Your brain isn't recording reality. It's predicting it. Understanding that one shift explains why psychedelics heal, why therapy matters, and why resistance isn't what we think.
New NIH research reveals that semaglutide sparks different responses inside appetite-controlling brain cells, offering fresh insight into why GLP-1 weight-loss drugs don’t work the same for everyone.
All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.
Merck is racing to defend its leadership in the market for cancer drugs ahead of Keytruda’s looming patent cliff. A clinical ...
BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...
Go behind the scenes of the Cancer Calculus investigation, and hear insights about Merck's cancer drug Keytruda from ICIJ's ...
Read all the latest news headline updates on cancer drugs. Get all the cancer drugs breaking news updates, videos, photostories and more at Business Standard.
BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a ...
The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results